Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 29

BRCA1 and BRCA2 testing in pancreatic cancer can reveal hereditary risk and DNA-repair targets. Learn germline vs somatic results, VUS meaning, treatment impact, and family testing.

BRCA1 and BRCA2 Test for Pancreatic Cancer: Hereditary Risk, DNA Repair,...

CA 19-9 is the main blood marker used to monitor pancreatic cancer. Learn what high levels mean, how bile duct obstruction affects results, normal cutoffs, and follow-up steps.

CA 19-9 Test for Pancreatic Cancer: High Levels, Monitoring, and Bile...

CEA helps monitor colon cancer and may signal recurrence, but benign conditions can also raise it. Learn typical ranges, false-positive causes, surveillance use, and next steps.

CEA Test for Colon Cancer: High Levels, Monitoring, Recurrence, and Benign...

CEA can rise in pancreatic cancer but is usually a secondary marker to CA 19-9. Learn typical CEA ranges, benign causes, monitoring uses, limitations, and next steps.

CEA Test for Pancreatic Cancer: Tumor Marker Levels, Monitoring, and Result...

Cholangiocarcinoma Biomarker Panel: CA 19-9, FGFR2, IDH1, IDH2, and Molecular Profile

CLDN18.2 testing uses gastric cancer tissue to measure claudin 18.2 expression. Learn the ≥75% positivity threshold, IHC scoring, treatment meaning, and key limitations.

CLDN18.2 Test for Gastric Cancer: Claudin 18.2 Expression Score and Tumor...

A colorectal cancer biomarker panel combines KRAS, NRAS, BRAF, MSI/MMR, CEA, and expanded molecular tests to guide targeted therapy, immunotherapy, hereditary workup, and monitoring.

Colorectal Cancer Biomarker Panel: KRAS, NRAS, BRAF, MSI, CEA, and Molecular...

DCP, also called PIVKA-II, is a liver cancer biomarker that can rise in HCC or vitamin K-related conditions. Learn cutoffs, false positives, monitoring uses, and next steps.

Des-Gamma-Carboxy Prothrombin (DCP) Test: Liver Cancer Marker, HCC Monitoring, and Meaning

EBER in situ hybridization identifies EBV-associated gastric cancer. Learn what positive and negative results mean, why blood EBV tests differ, and how EBV fits with gastric biomarkers.

EBV Test for Gastric Cancer: Epstein-Barr Virus Tumor Marker and Molecular...

FGFR2 fusion testing identifies actionable rearrangements in intrahepatic cholangiocarcinoma. Learn positive-result meaning, RNA vs DNA testing, targeted therapy, and resistance.

FGFR2 Fusion Test for Cholangiocarcinoma: Gene Fusion, Positive Result, and Molecular...

Gastric Cancer Biomarker Panel: HER2, PD-L1, MSI, CLDN18.2, EBV, and Molecular...

Understand Gastrointestinal Stromal Tumor (GIST) Biomarker Panel KIT, PDGFRA, DOG1, and Tumor Diagnosis: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

Gastrointestinal Stromal Tumor (GIST) Biomarker Panel: KIT, PDGFRA, DOG1, and Tumor...

GI Cancer Biomarker Panel: CEA, CA 19-9, MSI, KRAS, BRAF, HER2,...

Understand Guardant Reveal Test Colorectal Cancer ctDNA MRD and Recurrence Monitoring: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

Guardant Reveal Test: Colorectal Cancer ctDNA MRD and Recurrence Monitoring

Understand HER2 Test for Colon Cancer HER2 Expression, Amplification, and Tumor Marker Meaning: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

HER2 Test for Colon Cancer: HER2 Expression, Amplification, and Tumor Marker...

Understand HER2 Test for Gastric Cancer HER2 Expression, IHC/FISH Status, and Amplification: what the test measures, how results are interpreted, treatment implications, limitations, and practical next steps.

HER2 Test for Gastric Cancer: HER2 Expression, IHC/FISH Status, and Amplification

1...282930...137 Page 29 of 137